Wlosik, J.
Fattori, S.
Rochigneux, P.
Goncalves, A.
Olive, D.
Chretien, A. S. http://orcid.org/0000-0003-4685-5568
Funding for this research was provided by:
INCa (2012-064/2019-038)
ITMO cancer (2014-P032760)
Fondation ARC (SIGNIT202001327)
Fondation de France (00076207)
Fondation pour la Recherche Médicale (DEQ 20180339209)
Article History
Received: 15 September 2022
Accepted: 31 October 2022
First Online: 21 November 2022
Declarations
:
: D. O. is a cofounder and shareholder of ImCheck Therapeutics, Alderaan Biotechnology and Emergence Therapeutics and has research funds from ImCheck Therapeutics, Alderaan Biotechnology, Cellectis and Emergence Therapeutics. The other authors declare no conflicts of interest.